Interestingly, in ERα-positive breast cancer cells (MCF-7 and T47D), Res acts as an ERα antagonist by reducing the ability of this receptor subtype to activate AKT kinase phosphorylation and reducing NGB levels [49]. This evidence concerns the gene ESR1 and breast carcinoma.